It is alleged within the complaint that Biogen made misleading and false statements to the public throughout the Class Period and failed to disclose material adverse facts about Biogen’s business, operational, and compliance policies. Specifically, Biogen made misleading and/or false statements concerning: (1) Study 302, viewed independently, did not provide convincing evidence in support of the effectiveness of aducanumab; (2) Study 103 did not provide convincing evidence of the effectiveness of aducanumab; (3) Study 302 could not be considered as primary evidence of aducanumab’s effectiveness for the treatment of Alzheimer’s disease in light of the results of the exploratory analyses of Study 301 and 302, and the results of Study 103; (4) the totality of the data did not provide sufficient evidence to support aducanumab’s efficacy for the treatment of Alzheimer’s disease; and (5) Biogen’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times as a result.

Biogen, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067